Specificity requirement for FDC and concomitant medication [Bioanalytics]

posted by qualityassurance – 2023-07-07 11:06 (459 d 21:16 ago) – Posting: # 23659
Views: 1,762

Hi Karthik,

My opinion is that your validation should mimic the actual study condition. In BE studies of FDC, plasma samples contains all the analytes of interest and hence CC/QC during validation should contain the other analyte at ULOQ concentration or cmax concentration.

What is opinion of other (bioanalytical) experts?

Regards,
qualityassurance

Complete thread:

UA Flag
Activity
 Admin contact
23,249 posts in 4,885 threads, 1,653 registered users;
57 visitors (0 registered, 57 guests [including 5 identified bots]).
Forum time: 08:23 CEST (Europe/Vienna)

I have never in my life learned anything
from any man who agreed with me.    Dudley Field Malone

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5